Original BioMedicals
Original Biomed is a company focused on developing new drugs with innovative delivery systems, emphasizing new formulations, dosages, and indications. They aim to improve efficacy, reduce side effects, and repurpose existing drugs to shorten development time and save lives. Their R&D process includes synthesis, purification, formulation design, and safety testing, with clinical production conducted by cGMP-certified manufacturers.
Industries
Nr. of Employees
small (1-50)
Original BioMedicals
Tainan City, Xinshi District, Nanke 2nd Road, No. 9, 2F-1
Patents
Pharmaceutical composition used for reducing damage caused by free radicals
US-9700623-B2
View DetailsControlled release method for a pharmaceutical composition composed of chelating complex micelles
US-9597406-B2
View DetailsMethod of manufacturing a pharmaceutical composition having chelating type complex micelles
US-9211341-B2
View Details
Pharmaceutical composition used for reducing damage caused by free radicals
US-9700623-B2
View DetailsControlled release method for a pharmaceutical composition composed of chelating complex micelles
US-9597406-B2
View DetailsMethod of manufacturing a pharmaceutical composition having chelating type complex micelles
US-9211341-B2
View DetailsProducts
Intravenous iron dextran injection (development project)
Development project for an intravenous iron dextran formulation indicated for patients who cannot take or do not respond to oral iron therapy.
Nanoemulsion sustained-release Vitamin C + E product (development project)
Nanoemulsion-based sustained-release formulation of vitamin C and E developed in collaboration with an external partner; company supplies core raw materials under contract.
OBM-A01 (development project for radiation injury prevention/treatment)
Development-stage project focused on prevention or treatment of radiation injury, advanced under a reformulation/regulatory strategy.
OBM-B01 (development project for inhalation cyanide poisoning treatment)
Development-stage project targeting prevention or treatment of inhalation cyanide poisoning (e.g., fire inhalation), pursued via reformulation and accelerated regulatory strategies.
CCM-CL (development project)
Listed development project; specific indication and technical details not provided on the sourced pages.
NE Butorphanol (development project)
Listed development project using nanoemulsion or related delivery technologies; specific details not provided on the sourced pages.
Intravenous iron dextran injection (development project)
Development project for an intravenous iron dextran formulation indicated for patients who cannot take or do not respond to oral iron therapy.
Nanoemulsion sustained-release Vitamin C + E product (development project)
Nanoemulsion-based sustained-release formulation of vitamin C and E developed in collaboration with an external partner; company supplies core raw materials under contract.
OBM-A01 (development project for radiation injury prevention/treatment)
Development-stage project focused on prevention or treatment of radiation injury, advanced under a reformulation/regulatory strategy.
OBM-B01 (development project for inhalation cyanide poisoning treatment)
Development-stage project targeting prevention or treatment of inhalation cyanide poisoning (e.g., fire inhalation), pursued via reformulation and accelerated regulatory strategies.
CCM-CL (development project)
Listed development project; specific indication and technical details not provided on the sourced pages.
NE Butorphanol (development project)
Listed development project using nanoemulsion or related delivery technologies; specific details not provided on the sourced pages.
Services
End-to-end preclinical R&D services covering synthesis, purification, analytical/method development, formulation design, and preclinical safety testing to prepare candidates for clinical development.
Development of sustained-release nanoemulsion formulations and supply of core formulation materials to partner companies.
Management and coordination of clinical-stage manufacturing through cGMP-certified contract manufacturing organizations.
Execution of collaborative development agreements, MOUs, and commercial partnerships to advance product development and market entry.
End-to-end preclinical R&D services covering synthesis, purification, analytical/method development, formulation design, and preclinical safety testing to prepare candidates for clinical development.
Development of sustained-release nanoemulsion formulations and supply of core formulation materials to partner companies.
Management and coordination of clinical-stage manufacturing through cGMP-certified contract manufacturing organizations.
Execution of collaborative development agreements, MOUs, and commercial partnerships to advance product development and market entry.
Expertise Areas
- Drug delivery systems
- Reformulation and 505(b)(2)-style development
- Nanoformulation development (nanoemulsion)
- Controlled-release therapeutics
Key Technologies
- Nanoemulsion
- Composite micelle carriers
- Triggered/controlled-release systems
- Particle size engineering
News & Updates
The company signed a contract with S Company, focusing on the development of extended-release Vitamin C+E products using nan-emulsion technology, with exclusive supply of core raw materials.
Original Biomed, a platform company with R&D strength and rich product resources, signed a memorandum with Nanjing Xinyu Pharmaceutical and Jiangxi Rongchang Medical Trade to develop the market for Ruxi Gan Iron Injection, leveraging their respective advantages.
The company received an Australian invention patent for a nasal delivery composition and method, patent number 2022259787.
The company obtained a Chinese invention patent for the same nasal delivery composition and method, patent number 8016515.
The company signed a contract with S Company, focusing on the development of extended-release Vitamin C+E products using nan-emulsion technology, with exclusive supply of core raw materials.
Original Biomed, a platform company with R&D strength and rich product resources, signed a memorandum with Nanjing Xinyu Pharmaceutical and Jiangxi Rongchang Medical Trade to develop the market for Ruxi Gan Iron Injection, leveraging their respective advantages.
The company received an Australian invention patent for a nasal delivery composition and method, patent number 2022259787.
The company obtained a Chinese invention patent for the same nasal delivery composition and method, patent number 8016515.